Next Article in Journal
Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid
Next Article in Special Issue
Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology
Previous Article in Journal
SIRT1 Expression and Regulation in the Primate Testis
Previous Article in Special Issue
Endoglin in the Spotlight to Treat Cancer

The Role of Endoglin in Hepatocellular Carcinoma

Division of General Surgery, Far Eastern Memorial Hospital, New Taipei 22060, Taiwan
Department of Hepatogastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, Chang-Gung University, Taoyuan City 33305, Taiwan
Institute of Microbiology and Immunology, National Yang-Ming Chiao-Tung University, Taipei City 11221, Taiwan
Author to whom correspondence should be addressed.
Academic Editors: Lukas J.A.C. Hawinkels, Marie-José Goumans and J.B. Bernd Helms
Int. J. Mol. Sci. 2021, 22(6), 3208;
Received: 11 January 2021 / Revised: 19 March 2021 / Accepted: 19 March 2021 / Published: 22 March 2021
(This article belongs to the Special Issue Endoglin in Health and Disease)
Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise. View Full-Text
Keywords: endoglin; hepatocellular carcinoma; angiogenesis endoglin; hepatocellular carcinoma; angiogenesis
Show Figures

Figure 1

MDPI and ACS Style

Jeng, K.-S.; Sheen, I.-S.; Lin, S.-S.; Leu, C.-M.; Chang, C.-F. The Role of Endoglin in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2021, 22, 3208.

AMA Style

Jeng K-S, Sheen I-S, Lin S-S, Leu C-M, Chang C-F. The Role of Endoglin in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2021; 22(6):3208.

Chicago/Turabian Style

Jeng, Kuo-Shyang; Sheen, I-Shyan; Lin, Shu-Sheng; Leu, Chuen-Miin; Chang, Chiung-Fang. 2021. "The Role of Endoglin in Hepatocellular Carcinoma" Int. J. Mol. Sci. 22, no. 6: 3208.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop